Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide 10 mg is the fourth dose in the Mounjaro titration ladder, typically reached after around twelve weeks on treatment. By this point, most people have worked through the 2.5 mg, 5 mg and 7.5 mg doses. Whether 10 mg becomes your maintenance dose or a stepping stone toward 12.5 mg or 15 mg is a clinical decision, not a personal one — and it is made by your prescriber, not by you alone. These are prescription-only medicines assessed individually for each patient.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro's licensed dosing schedule exists primarily to let your body adjust. The 2.5 mg starting dose is designed to reduce the likelihood of nausea and digestive discomfort, it does not deliver the same clinical effect as the higher doses. From there, most people move up in roughly four-week steps: 2.5 mg, then 5 mg, then 7.5 mg, and then 10 mg. You can read about the broader tirzepatide dosing schedule if you want to see all six steps laid out together.
By the time 10 mg arrives, your system has usually had two to three months to adapt. Many people notice that the GI side effects that showed up early (nausea, loose stools, a general unsettled stomach) have largely settled. That adjustment period is one reason the schedule is paced the way it is. The NHS medicines information for tirzepatide confirms that titration is gradual, with each increase based on tolerability rather than a fixed calendar.
Each Mounjaro KwikPen holds four weekly doses, so a single pen covers one calendar month. Moving to the 10 mg tirzepatide dose means starting a new pen at that strength, the pen format stays the same, only the concentration changes. Storage remains refrigerated at 2–8°C; your Patient Information Leaflet gives the exact room-temperature window if you need to travel.
A prescriber considering whether to move you to 10 mg is looking at two things above all else: how much weight you have lost so far, and how well you tolerated 7.5 mg. Both matter. If side effects at 7.5 mg were significant and are still present, staying longer at that dose is often the right call. If tolerability has been good and weight loss has plateaued, moving up makes clinical sense.
This is why the titration conversation with your prescriber is not a formality. At nume, a named clinician reads your update before any repeat supply is confirmed, the same-day clinical review that applies to your first order applies to every subsequent one. The clinical team at nume assesses the whole picture, not just the dose number.
It is also worth knowing that 10 mg does not suit everyone as a long-term landing point, and that is entirely normal. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that higher doses (12.5 mg and 15 mg) produced greater average weight reduction than lower ones, but individual responses vary considerably. Some people achieve clinically meaningful weight loss at 10 mg and stay there. Others find that moving to the 15 mg dose gives an additional benefit. The right answer depends on your response and tolerability, assessed by your prescriber.
For most people, the side-effect picture at 10 mg looks different from early treatment. The sharp nausea many people experience in the first few weeks at 2.5 mg and 5 mg tends to ease as the body acclimatises. Moving to a higher dose can bring a temporary return of GI symptoms (loose stools, reduced appetite, occasional reflux) but these generally settle within one to two weeks of a dose change.
The NHS tirzepatide medicines page lists the most commonly reported side effects across the full dose range: nausea, diarrhoea, vomiting, constipation, indigestion and injection-site reactions. Fatigue and headache appear less often. None of these are reasons to stop treatment on their own, but any side effect that is severe or persistent should be discussed with your prescriber promptly.
One thing the Mounjaro overview page covers in more detail is the rare but serious risk of pancreatitis. The MHRA issued a Drug Safety Update in January 2026 flagging acute pancreatitis as an infrequent but known risk for GLP-1 medicines: severe abdominal pain that spreads toward the back, with or without vomiting, needs urgent medical attention rather than a wait-and-see approach. Report any suspected side effect you are not sure about through the MHRA Yellow Card scheme.
Moving up the dose schedule also means the cost of private treatment changes. A 10 mg pen is priced differently from a 5 mg or 7.5 mg pen, and understanding how Mounjaro pricing works across doses is worth doing before you reach this stage rather than after. One transparent price at nume covers the clinical review, prescription, the treatment itself and free next-working-day tracked delivery, there is no separate consultation fee added on top, and no subscription that auto-renews without your knowledge.
If you are currently at a lower dose and wondering what to expect as you progress, the 5 mg dosage page covers that earlier stage in detail. When you are ready to discuss whether 10 mg is the right next step for you, or whether it should become your maintenance dose, speaking to our prescribers is the clearest way to get a clinical answer rather than a general one.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.